Chemotherapy in low-grade gliomas

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 694-701

  Viaccoz, Aurélien ^a,b,c,d   Lekoubou, Alain ^a   Ducray, François ^a,b,c,d  

^a HÔPITAL NEUROLOGIQUE   (France)

^b INSERM   (France)

^c CNRS   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

chemotherapy; low grade glioma; PCV; temozolomide

Indexed keywords

HYDROXYUREA; IMATINIB; ISOCITRATE DEHYDROGENASE 1; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DRUG WITHDRAWAL; EPILEPSY; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; METHYLATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; DACARBAZINE; GLIOMA; HUMANS; LOMUSTINE; PROCARBAZINE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84868206990     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328357f503     Document Type: Review

References (58)

1. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003; 53:524-528.
2. Ricard D, Idbaih A, Ducray F, et al. Primary brain tumours in adults. Lancet 2012; 379:1984-1996.
3. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg 2011; 115:948-965.
4. Gilbert MR, Lang FF. Management of patients with low-grade gliomas. Neurol Clin 2007; 25:1073-1088; ix.
5. Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of lowgrade gliomas: report of an EFNS-EANO-Task Force. Eur J Neurol 2010; 17:1124-1133.
6. De Witt Hamer PC, Gil Robles S, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 2012; 30:2559-2565.
7. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the longterm outcome of low-grade hemispheric gliomas. J Clin Oncol 2008; 26:1338-1345.
8. Van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366:985-990.
9. Weller M. Chemotherapy for low-grade gliomas: when? how? how long? Neuro Oncol 2010; 12:1013.
10. Douw L, Klein M, Fagel S, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009; 8:810-818.
11. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46:203-207.
12. Buckner JC, Gesme D Jr, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003; 21:251-255.
13. Higuchi Y, Iwadate Y, Yamaura A. Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology 2004; 63:2384-2386.
14. Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005; 103:802-809.
15. Catenoix H, Honnorat J, Cartalat-Carel S, et al. [Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents]. Rev Neurol (Paris) 2006; 162:1069-1075.
16. Ty AU, See SJ, Rao JP, et al. Oligodendroglial tumor chemotherapy using 'decreased-dose-intensity' PCV: a Singapore experience. Neurology 2006; 66:247-249.
17. Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 2007; 14:391-398.
18. Peyre M, Cartalat-Carel S, Meyronet D, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 2010; 12:1078-1082.
19. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003; 21:646-651.
20. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003; 14:1715-1721.
21. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22:3133-3138.
22. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006; 106:1759-1765.
23. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007; 68:1831-1836.
24. Pouratian N, Gasco J, Sherman JH, et al. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 2007; 82:281-288.
25. Tosoni A, Franceschi E, Ermani M, et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 2008; 89:179-185.
26. Kesari S, Schiff D, Drappatz J, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 2009; 15: 330-337.
27. Soffietti R, Ruda R, Bradac GB, et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998; 43:1066-1073.
28. Van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998; 51:1140-1145.
29. Kaloshi G, Sierra Del Rio M, Ducray F, et al. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. J Neurooncol 2010; 100:439-441.
30. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003; 14:1722-1726.
31. Van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTCBrain TumorGroup phase II study 26972. Ann Oncol 2003; 14:599-602.
32. Van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21:2525-2528.
33. Taal W, Dubbink HJ, Zonnenberg CB, et al. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neurooncol 2011; 13:235-241.
34. Ducray F. Chemotherapy for diffuse low-grade gliomas in adults. Rev Neurol (Paris) 2011; 167:673-679.
35. Sherman JH, Moldovan K, Yeoh HK, et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 2011; 114:1617-1621.
36. Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 2007; 61:484-490.
37. Shaw E, Wang M, Coons S. Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation Therapy(RT) versus RT + procarbazine, CCNU and (PCV) vincristine chemotherapy for adult low grade glioma(LGG). J Clin Oncol 2008; 26:abstract 2006.
38. Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep 2010; 10:224-231.
39. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer 2012. doi: 10.1002/cncr.26541.
40. Duffau H. New concepts in surgery of WHO grade II gliomas: functional brain mapping, connectionism and plasticity-a review. J Neurooncol 2006; 79:77-115.
41. Spena G, Garbossa D, Barletta L, et al. Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection-case report. Neurol Med Chir (Tokyo) 2010; 50:410-413.
42. Voloschin AD, Louis DN, Cosgrove GR, Batchelor TT. Neoadjuvant temozolomide followed by complete resection of a 1p-and 19q-deleted anaplastic oligoastrocytoma: case study. Neurooncol 2005; 7:97-100.
43. Blonski M, Taillandier L, Herbet G, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol 2012; 106:353-366.
44. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010; 28:4601-4608.
45. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27:5874-5880.
46. Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neurooncol 2011; 13:649-659.
47. Liu R, Solheim K, Polley MY, et al. Quality of life in low-grade glioma patients receiving temozolomide. Neurooncol 2009; 11:59-68.
48. Lashkari HP, Saso S, Moreno L, et al. Using different schedules of temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. J Neurooncol 2011; 105:135-147.
49. Van den Bent M, Wefel J, Schiff D, et al. Response assessment in neurooncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011; 12:583-593.
50. Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 2006; 60:380-383.
51. Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological MRI followup of low-grade glioma: a plead for systematic measurement of growth rates. Neurosurgery 2012. doi: 10.1227/NEU.0b013e31826213de.
52. Pallud J, Llitjos JF, Dhermain F, et al. Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neurooncol 2012; 14:496-505.
53. Guillevin R, Menuel C, Taillibert S, et al. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. Br J Cancer 2011; 104:1854-1861.
54. Ducray F, El Hallani S, Idbaih A. Diagnostic and prognostic markers in gliomas. Curr Opin Oncol 2009; 21:537-542.
55. Ducray F, Idbaih A, Wang XW, et al. Predictive and prognostic factors for gliomas. Expert Rev Anticancer Ther 2011; 11:781-789.
56. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006; 60:740-743.
57. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75:1560-1566.
58. Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009; 73:1792-1795.